BACKGROUND: Exposure of tissue factor (TF) to the circulation during coronary stent implantation initiates coagulation activation and may contribute to the risk of thrombotic complications. In this study, we investigated whether inhibition of TF-factor VIIa by recombinant Nematode Anti-coagulant Protein c2 (rNAPc2) is able to suppress haemostatic and inflammatory activity in patients undergoing elective intracoronary stenting. METHODS: In a randomised, double-blind design, 102 patients received eitherplacebo or rNAPc2 (biological half-life >50 hours) at doses of 3.5, 5.0, 7.5 and 10.0 μg/kg as a single subcutaneous administration two to six hours before angioplasty. All patients also received aspirin, clopidogrel and unfractionated heparin (activated clotting time >250 seconds during angioplasty). Serial blood samples were collected before and after the intervention. RESULTS: At 30 hours after stenting, all rNAPc2 treatment groups but not the placebo group demonstrated a reduction from baseline of prothrombin fragment F1+2 and D-dimer plasma levels (to 23 and 12% below baseline values at the highest dose, respectively), which were significantly lower in three rNAPc2 groups compared with placebo (p≤0.03). TF plasma levels were initially reduced in all rNAPc2 groups and returned to baseline values 18 hours after stent implantation. These three markers all increased to above baseline values in the placebo group. Levels of P-selectin, antithrombin III and interleukin-8 were not or only slightly affected by the intervention or by rNAPc2, whereas a significant 2.8 to 4.1 fold increase of C-reactive protein plasma levels was found in all patient groups after the procedure. CONCLUSION: In contrast to the inflammatory response, coagulation activation after elective coronary stent implantation, which is observed in spite of the use of multiple antithrombotic drugs, can be attenuated by inhibition of the TF-factor VIIa complex using rNAPc2. Inhibition of the TF-mediated pathway of coagulation may be an important target to prevent thrombotic complications after coronary stenting.
RCT Entities:
BACKGROUND: Exposure of tissue factor (TF) to the circulation during coronary stent implantation initiates coagulation activation and may contribute to the risk of thrombotic complications. In this study, we investigated whether inhibition of TF-factor VIIa by recombinant Nematode Anti-coagulant Protein c2 (rNAPc2) is able to suppress haemostatic and inflammatory activity in patients undergoing elective intracoronary stenting. METHODS: In a randomised, double-blind design, 102 patients received either placebo or rNAPc2 (biological half-life >50 hours) at doses of 3.5, 5.0, 7.5 and 10.0 μg/kg as a single subcutaneous administration two to six hours before angioplasty. All patients also received aspirin, clopidogrel and unfractionated heparin (activated clotting time >250 seconds during angioplasty). Serial blood samples were collected before and after the intervention. RESULTS: At 30 hours after stenting, all rNAPc2 treatment groups but not the placebo group demonstrated a reduction from baseline of prothrombin fragment F1+2 and D-dimer plasma levels (to 23 and 12% below baseline values at the highest dose, respectively), which were significantly lower in three rNAPc2 groups compared with placebo (p≤0.03). TF plasma levels were initially reduced in all rNAPc2 groups and returned to baseline values 18 hours after stent implantation. These three markers all increased to above baseline values in the placebo group. Levels of P-selectin, antithrombin III and interleukin-8 were not or only slightly affected by the intervention or by rNAPc2, whereas a significant 2.8 to 4.1 fold increase of C-reactive protein plasma levels was found in all patient groups after the procedure. CONCLUSION: In contrast to the inflammatory response, coagulation activation after elective coronary stent implantation, which is observed in spite of the use of multiple antithrombotic drugs, can be attenuated by inhibition of the TF-factor VIIa complex using rNAPc2. Inhibition of the TF-mediated pathway of coagulation may be an important target to prevent thrombotic complications after coronary stenting.
Authors: Arno H M Moons; Ron J G Peters; Nick R Bijsterveld; Jan J Piek; Martin H Prins; George P Vlasuk; William E Rote; Harry R Büller Journal: J Am Coll Cardiol Date: 2003-06-18 Impact factor: 24.094
Authors: A Buffon; G Liuzzo; L M Biasucci; P Pasqualetti; V Ramazzotti; A G Rebuzzi; F Crea; A Maseri Journal: J Am Coll Cardiol Date: 1999-11-01 Impact factor: 24.094
Authors: P L Giesen; B S Fyfe; J T Fallon; M Roque; M Mendlowitz; M Rossikhina; A Guha; J J Badimon; Y Nemerson; M B Taubman Journal: Thromb Haemost Date: 2000-04 Impact factor: 5.249
Authors: J St Pierre; L Y Yang; K Tamirisa; D Scherrer; P De Ciechi; P Eisenberg; E Tolunay; D Abendschein Journal: Arterioscler Thromb Vasc Biol Date: 1999-09 Impact factor: 8.311
Authors: J D Marmur; S V Thiruvikraman; B S Fyfe; A Guha; S K Sharma; J A Ambrose; J T Fallon; Y Nemerson; M B Taubman Journal: Circulation Date: 1996-09-15 Impact factor: 29.690
Authors: Y Asada; S Hara; A Tsuneyoshi; K Hatakeyama; A Kisanuki; K Marutsuka; Y Sato; Y Kamikubo; A Sumiyoshi Journal: Thromb Haemost Date: 1998-09 Impact factor: 5.249